Clinical Trial Detail

NCT ID NCT02414139
Title Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Capmatinib

Age Groups: adult senior

Additional content available in CKB BOOST